Home > Publications Database > N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease. > print

001     154287
005     20240320115505.0
024 7 _ |a pmc:PMC8082844
|2 pmc
024 7 _ |a 10.1111/nan.12637
|2 doi
024 7 _ |a pmid:32497293
|2 pmid
024 7 _ |a 0305-1846
|2 ISSN
024 7 _ |a 1365-2990
|2 ISSN
024 7 _ |a altmetric:83503382
|2 altmetric
037 _ _ |a DZNE-2021-00141
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zampar, S.
|b 0
245 _ _ |a N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease.
260 _ _ |a Oxford [u.a.]
|c 2020
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1617103238_11425
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1365-2990 not unique: **3 hits**.
520 _ _ |a The deposition of amyloid-β (Aβ) peptides in the form of extracellular plaques in the brain represents one of the classical hallmarks of Alzheimer's disease (AD). In addition to 'full-length' Aβ starting with aspartic acid (Asp-1), considerable amounts of various shorter, N-terminally truncated Aβ peptides have been identified by mass spectrometry in autopsy samples from individuals with AD.Selectivity of several antibodies detecting full-length, total or N-terminally truncated Aβ species has been characterized with capillary isoelectric focusing assays using a set of synthetic Aβ peptides comprising different N-termini. We further assessed the N-terminal heterogeneity of extracellular and vascular Aβ peptide deposits in the human brain by performing immunohistochemical analyses using sporadic AD cases with antibodies targeting different N-terminal residues, including the biosimilar antibodies Bapineuzumab and Crenezumab.While antibodies selectively recognizing Aβ1-x showed a much weaker staining of extracellular plaques and tended to accentuate cerebrovascular amyloid deposits, antibodies detecting Aβ starting with phenylalanine at position 4 of the Aβ sequence showed abundant amyloid plaque immunoreactivity in the brain parenchyma. The biosimilar antibody Bapineuzumab recognized Aβ starting at Asp-1 and demonstrated abundant immunoreactivity in AD brains.In contrast to other studied Aβ1-x -specific antibodies, Bapineuzumab displayed stronger immunoreactivity on fixed tissue samples than with sodium dodecyl sulfate-denatured samples on Western blots. This suggests conformational preferences of this antibody. The diverse composition of plaques and vascular deposits stresses the importance of understanding the roles of various Aβ variants during disease development and progression in order to generate appropriate target-developed therapies.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Abeta
|2 Other
650 _ 7 |a Alzheimer disease
|2 Other
650 _ 7 |a N-terminal truncation
|2 Other
650 _ 7 |a amyloid
|2 Other
650 _ 7 |a antibody
|2 Other
650 _ 7 |a capillary isoelectric focusing immunoassay
|2 Other
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal, Humanized: pharmacology
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Peptide Fragments: metabolism
|2 MeSH
650 _ 2 |a Plaque, Amyloid: metabolism
|2 MeSH
700 1 _ |a Klafki, H. W.
|b 1
700 1 _ |a Sritharen, K.
|b 2
700 1 _ |a Bayer, T. A.
|b 3
700 1 _ |a Wiltfang, J.
|0 P:(DE-2719)2811317
|b 4
|u dzne
700 1 _ |a Rostagno, A.
|b 5
700 1 _ |a Ghiso, J.
|b 6
700 1 _ |a Miles, L. A.
|b 7
700 1 _ |a Wirths, O.
|0 P:(DE-HGF)0
|b 8
773 _ _ |a 10.1111/nan.12637
|g Vol. 46, no. 7, p. 673 - 685
|0 PERI:(DE-600)2008293-9
|n 7
|p 673 - 685
|t Neuropathology & applied neurobiology
|v 46
|y 2020
|x 1365-2990
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154287/files/nan.12637.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154287/files/nan.12637.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154287
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811317
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROPATH APPL NEURO : 2021
|d 2022-11-16
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-16
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROPATH APPL NEURO : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Alzheimer Biomarker and Clinical Study Group
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1410006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21